ENDO PRESENTS NEW COLLAGENESE CLOSTRIDIUM HISTOLYTICUM DATA

Endo International has announced initial results from a Phase I study (EN3835–105) evaluating collagenase clostridium histolyticum (CCH) for the treatment of plantar fibromatosis. The data are being presented as an e-poster at the American Podiatric Medical Association (APMA) Annual Scientific Meeting, The National, in Denver.

 

Dr. Richard Pollak

 

"The current treatment of plantar fibromatosis is primarily focused on relieving pain and swelling. Options to effectively treat this condition and remove the nodules are limited to more invasive surgical procedures," said Richard Pollak, DPM, MS, the lead study author and president of Endeavor Clinical Trials and San Antonio Podiatry Associates in Texas. "These early-phase data provide new evidence suggesting that CCH could potentially be a non-surgical option to treat this condition."

 Courtesy of Barry Block, editor of PM News